
==== Front
BMC Cardiovasc Disord
BMC Cardiovasc Disord
BMC Cardiovascular Disorders
1471-2261
BioMed Central London

4177
10.1186/s12872-024-04177-3
Research
Association between triglyceride-glucose index and all-cause mortality in patients underwent transcatheter aortic valve replacement
Fan Jiaqi 12
Aihemaiti Ailifeire 13
Yidilisi Abuduwufuer 13
Liu Xianbao liuxb@zju.edu.cn

13456
Wang Jian’an wangjianan111@zju.edu.cn

13456
1 https://ror.org/059cjpv64 grid.412465.0 Department of Cardiology, Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
2 grid.38142.3c 000000041936754X Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA USA
3 grid.13402.34 0000 0004 1759 700X Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
4 State Key Laboratory of Transvascular Implantation Devices, Jiefang Road 88, Hangzhou, 310009 China
5 grid.13402.34 0000 0004 1759 700X Cardiovascular Key Laboratory of Zhejiang Province, Jiefang Road 88, Hangzhou, 310009 China
6 https://ror.org/059cjpv64 grid.412465.0 Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009 China
23 9 2024
23 9 2024
2024
24 50823 4 2024
9 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Backgrounds

The prognosis of the triglyceride-glucose (TyG) index, a validated surrogate marker for insulin resistance, in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) remains unknown.

Methods

This study consecutively enrolled patients diagnosed with severe AS who underwent TAVR in a Chinese tertiary hospital from March 2013 to September 2023. Participants were stratified based on the TyG index cut-off value. Cox proportional hazards regression models were utilized to explore the association between the TyG index and all-cause mortality, including an assessment of interactions between the TyG index and various covariates on mortality outcomes.

Results

Among 1045 patients (mean age 74.7 years, 58.2% male), there was 134 all-cause mortality, resulting in a crude mortality rate of 64.3 per 1000 person-years. Adjusting for age, sex, body mass index, smoking, hypertension, diabetes mellitus, bicuspid aortic valve, atrial fibrillation, Society of Thoracic Surgeons (STS) score, and left ventricular ejection fraction, a per-unit increase in the TyG index was associated with a 41% higher all-cause mortality risk (HR 1.41, 95% CI 1.03–1.93, p = 0.030). Notably, the relationship between the TyG index and all-cause mortality was significantly modified by age (pinteraction = 0.027), sex (pinteraction = 0.007), hypertension (pinteraction = 0.030), and STS score (pinteraction = 0.002).

Conclusions

A higher TyG index is significantly associated with an increased risk of all-cause mortality in AS patients after TAVR. These results underscore the importance of considering the TyG index in the prognostic evaluation of AS patients following TAVR.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12872-024-04177-3.

Keywords

Insulin resistance
Severe aortic stenosis
Transcatheter aortic valve replacement
Mortality
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Transcatheter aortic valve replacement (TAVR) has become a standard treatment for severe aortic stenosis (AS) [1–6]. While patients undergoing TAVR for severe AS often experience favorable short- and long-term outcomes, the presence of comorbidities such as hypertension, diabetes mellitus, metabolic syndrome, or chronic lung disease in this elderly population can hinder long-term prognosis [7–10]. Therefore, with increasing life expectancy, early identification of poor prognostic factors and the discovery of potential therapeutic targets are of critical importance.

Insulin resistance (IR) denotes reduced sensitivity and responsiveness to insulin’s action, often preceding the onset of type 2 diabetes mellitus by several years [11]. Mounting evidence indicates that IR and its associated conditions contribute to cardiovascular disease (CVD) development in both diabetic and nondiabetic individuals [12–14]. Individuals with IR are prone to various metabolic disorders, including hyperglycemia, dyslipidemia, and hypertension, all of which strongly correlate with adverse cardiovascular outcomes [14, 15]. IR is not only recognized as a causal factor but also as a predictor of CVD in both general populations and those with diabetes [16].

The triglyceride-glucose (TyG) index has been proposed as a reliable surrogate for IR, not requiring insulin quantification and making it applicable to individuals regardless of their insulin treatment status [17, 18]. A previous study reported that higher IR, as assessed by the TyG index, was associated with an increased risk of all-cause mortality in patients with moderate and severe AS [19]. However, there is currently a lack of data regarding the associations between the TyG index and all-cause mortality in AS patients undergoing TAVR.

Hence, this study aims to assess the relationship between insulin resistance, as evaluated by the TyG index, and all-cause mortality among severe AS patients undergoing TAVR.

Methods

Study design and population

The present study utilized patient data from the TORCH registry (Transcatheter Aortic Valve Replacement Single Center Registry in the Chinese Population, NCT02803294). The design and methods of the TORCH study have been previously described [20]. TORCH registry is a single-center prospective cohort study in Chinese population who underwent TAVR procedures for severe AS.

In the present study, a total of 1474 patients diagnosed with severe AS who underwent TAVR procedure at the Second Affiliated Hospital of Zhejiang University between March 2013 and September 2023 were consecutively enrolled. The inclusion criteria were as follows: (1) over 18 years old; (2) diagnosis of severe symptomatic aortic stenosis or regurgitation by echocardiography; (3) subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent; (4) the subject agrees to comply with specified follow-up evaluations and to return to the investigational site where the procedure was performed; (5) patients are technical and anatomical eligible for interventions. The exclusion criteria were as follows: (1) the first 100 TAVR cases in learning curve (N = 100); (2) underwent TAVR procedure for severe aortic regurgitation (N = 246); (3) periprocedural severe complications, like coronary rupture, coronary obstruction, aorta dissection, or unplanned conversion to surgical procedure (N = 37); (4) without data for baseline TyG index (N = 46). Finally, 1045 patients with severe AS underwent TAVR procedure were included for analysis (Fig. 1). This study was conducted following the Declaration of Helsinki and was approved by the Ethics Review Committee of the Second Affiliated Hospital of Zhejiang University.

Fig. 1 Flow chart for selecting patients with severe aortic stenosis from TORCH study for analysis

Data collection and definitions

Clinical data, including age, sex, height, weight, history of smoking, hypertension, diabetes mellitus, atrial fibrillation, chronic obstructive pulmonary disease, New York Heart Association functional classification, creatinine, fasting plasma glucose (FPG), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were extracted from electronic medical records. The body mass index (BMI) was calculated by dividing the weight in kilograms by the square of height in meters. The TyG index was computed using ln(TG [mg/dl] × FPG [mg/dl]/2). Indicators in the TyG index were calculated based on the fasting blood glucose and triglyceride indices of the patients at the time of admission. The classification of bicuspid AS was performed in multi-slice computed tomography imaging before TAVR [20]. The left ventricular ejection fraction was measured in echocardiography before TAVR. The TORCH registry database comprehensively archived all clinical, imaging, and follow-up data pertinent to this study, providing complete traceability of the data sources.

Outcome

Follow-up assessments were conducted at 30 days post-procedure and subsequently on an annual basis by our professional follow-up team. The majority of patients received follow-up care at our center, whereas others were monitored via telephone interviews. All follow-up data were collected into our database. The primary outcome of this study was all-cause mortality. We also evaluated the cardiovascular mortality as the secondary outcome. The duration of follow-up was defined as the time from the index TAVR procedure to the date of death or the last recorded follow-up. The follow-up of all patients who were included in this study was completed in September 2023.

Statistical analysis

Continuous variables were reported as means ± standard deviations (SD) for normally distributed data, or medians with interquartile ranges (IQR) for non-normally distributed data. Categorical data were expressed as counts and percentages. Based on the optimal cutoff value of the TyG index, patients were stratified into lower and higher TyG index groups. The optimal cutoff value for the TyG index was established for the prediction of the primary outcome via receiver operating characteristic (ROC) curve analysis. Group comparisons for continuous variables were conducted using the Student’s t-test for normally distributed data and the Mann-Whitney U test for non-normally distributed data. Categorical variables were analyzed using the Pearson chi-square test or Fisher’s exact test, depending on the expected frequencies.

Crude incidence rates for all-cause and cardiovascular mortality were reported as events per 1000 patient-years. The stratified incidence rates for all-cause and cardiovascular mortality were estimated within each TyG index category (lower or higher), with 95% confidence intervals (CIs) derived using the jackknife method. Cumulative survival rates for all-cause mortality, stratified by TyG index group (lower or higher), were computed using the Kaplan-Meier method and adjusted for age, sex, and BMI. Cox proportional hazards regression with a backward stepwise approach was employed to estimate hazard ratios (HRs) and 95% CIs for the relationship between the TyG index and mortality outcomes, both all-cause and cardiovascular. The proportional hazards assumption was tested using Schoenfeld residuals. Two multivariable models were constructed for adjustment: Model 1 included baseline age, sex, and BMI, whereas Model 2 further adjusted for smoking, hypertension, diabetes mellitus, BAV, atrial fibrillation, STS, and LVEF. Moreover, a landmark analysis excluding patients who experienced the outcome within the first 30 days was performed as sensitivity analysis.

Subgroup analyses were conducted to assess the consistency of the TyG index’s prognostic value for all-cause mortality across various baseline characteristics, including baseline age (< 75 and ≥ 75 years), sex, BMI (< 24 and ≥ 24 kg/m2), smoking status, hypertension, diabetes mellitus, BAV, atrial fibrillation, STS score (low risk for STS < 4% and intermediate/high risk for STS ≥ 4%), and LVEF (< 50% and ≥ 50%). Interaction terms for these subgroups were integrated into the Cox proportional hazards regression model to test for statistical interactions (p for interaction).

Statistical analyses were performed using STATA software, version 19.0 (StataCorp LP, College Station, TX), and R, version 4.2.3 (R Foundation for Statistical Computing, Vienna, Austria). A two-sided P value < 0.05 was considered statistically significant.

Results

The ROC curve analysis showed that the optimal TyG index threshold for predicting the primary outcome was 6.88. Table 1 shows the baseline characteristics of the 1045 patients with severe AS who underwent TAVR, grouped according to the optimal cut-off point of the TyG index. The mean age of all patients was 74.7 ± 7.2 years, of whom 608 (58.2%) were male. Patients with TyG index ≥ 6.88 had higher levels of TC, LDL-C, TG, FPG, DBP and BMI, lower levels of HDL-C, lower median age, lower proportions of COPD and higher proportions of males, hypertension and diabetes mellitus compared with patients with TyG index < 6.88.

Table 1 Baseline characteristics of participants

	Total Population
(n = 1045)	Lower TyG index
(< 6.88, n = 622)	Higher TyG index
(≥ 6.88, n = 423)	P value	
TyG index	6.76 (6.41–7.14)	6.49 (6.28–6.68)	7.25 (7.02–7.52)	< 0.001	
Age	74.7 ± 7.2	75.1 ± 7.4	74.0 ± 6.9	0.010	
Sex				0.015	
   Female	437 (41.8%)	241 (38.7%)	196 (46.3%)		
   Male	608 (58.2%)	381 (61.3%)	227 (53.7%)		
BMI, kg/m2	22.80 (20.30–25.00)	22.00 (19.60–24.30)	23.70 (21.50–25.80)	< 0.001	
Smoking	216 (20.7%)	133 (21.4%)	83 (19.6%)	0.490	
Hypertension	582 (55.7%)	304 (48.9%)	278 (65.7%)	< 0.001	
Diabetes mellitus	215 (20.6%)	82 (13.2%)	133 (31.4%)	< 0.001	
Atrial fibrillation	185 (17.7%)	116 (18.7%)	69 (16.3%)	0.331	
COPD	198 (18.9%)	132 (21.2%)	66 (15.6%)	0.023	
NYHA III/IV	787 (75.3%)	477 (76.7%)	310 (73.3%)	0.211	
STS	4.10 (2.29–7.52)	4.15 (2.33–7.65)	4.03 (2.25–7.35)	0.453	
Creatinine, mmol/L	73.0 (60.0–90.0)	73.0 (60.0–90.0)	72.0 (60.0-90.3)	0.860	
FPG, mmol/L	5.07 (4.61–5.76)	4.83 (4.45–5.23)	5.72 (5.07–6.85)	< 0.001	
Total Cholesterol, mmol/L	3.95 (3.35–4.75)	3.79 (3.24–4.51)	4.23 (3.51–5.04)	< 0.001	
TG, mmol/L	0.99 (0.77–1.36)	0.82 (0.67–0.98)	1.51 (1.23–1.87)	< 0.001	
LDL-C, mmol/L	2.04 (1.57–2.64)	1.89 (1.47–2.42)	2.30 (1.80–2.98)	< 0.001	
HDL-C, mmol/L	1.18 (1.01–1.41)	1.26 (1.08–1.47)	1.09 (0.93–1.27)	< 0.001	
BAV	573 (56.3%)	347 (57.5%)	226 (54.6%)	0.366	
LVEF	59.7 (49.2–65.5)	59.4 (48.1–65.8)	60.0 (50.4–65.1)	0.980	
Data are shown as mean ± SD or n (%). Baseline characteristics of the 1045 patients who underwent transcatheter aortic valve replacement, stratified by the optimal cutoff point of triglyceride glucose index

BAV, bicuspid aortic valve; BMI, body mass index; COPD, chronic obstructive pulmonary disease; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; TG, triglyceride; TyG, triglyceride-glucose

During a median follow-up of 17.59 months, a total of 134 (12.8%) all-cause mortality were recorded for analysis. Of these, 42 (4.0%) were cardiovascular mortality. Cox regression analysis of the association between the TyG index and mortality is shown in Table 2. In the model that measured the baseline TyG index as a continuous variable, although the relationship between the TyG index and all-cause mortality was not significant in model 1, the value of the relationship was highly significant after further adjustment for potential confounders in model 2. The association between TyG index and cardiovascular mortality was not significant despite further adjustment for potential confounders in model 2. In fully adjusted model 2, each 1-unit increase in the TyG index was associated with a 41% increase in the risk of all-cause mortality (HR 1.41, 95% CI 1.03–1.93, p = 0.03). Furthermore, in model 1, the risk of all-cause mortality was 1.62 times higher in the higher TyG index group compared with the lower TyG index group (HR 1.62, 95% CI 1.14–2.32, p = 0.008). In model 2, the relationship remains robust to the fact that the higher TyG index group increases the risk of all-cause mortality relative to the lower TyG index group after further adjustment for other potential confounders (HR 1.53, 95% CI 1.08–2.17, p = 0.017). A landmark analysis excluding patients who experienced the outcome within the first 30 days showed a similar results and were presented in Supplementary Table 1. Figure 2 shows Kaplan-Meier cumulative survival analysis curves for all-cause mortality adjusted for age, sex and BMI for the higher TyG index and lower TyG index groups. During a follow-up period of up to 8 years, a statistically significant difference in all-cause mortality was observed between the two groups.

Table 2 Association between the TyG index and mortality*

	Event/Total	IR (95% CI),
per 1000 person-years		Model 1		Model 2	
	HR (95% CI)	P value		HR (95% CI)	P value	
All-cause Mortality									
   Continuous (per unit)	134/1045 (12.8%)	64.3 (54.3–76.2)		1.32 (0.96–1.81)	0.085		1.41 (1.03–1.93)	0.030	
   Lower TyG index	72/622 (11.6%)	57.6 (45.7–72.6)		Reference	-		Reference	-	
   Higher TyG index	62/423 (14.7%)	74.3 (58.0-95.3)		1.62 (1.14–2.32)	0.008		1.53 (1.08–2.17)	0.017	
Cardiovascular Mortality									
   Continuous (per unit)	42/1043 (4.0%)	20.2 (14.9–27.3)		1.56 (0.92–2.65)	0.098		1.63 (0.94–2.84)	0.085	
   Lower TyG index	20/620 (3.2%)	16.0 (10.3–24.8)		Reference	-		Reference	-	
   Higher TyG index	22/423 (5.2%)	26.4 (17.4–40.1)		1.78 (0.97–3.28)	0.063		1.60 (0.85-3.00)	0.144	
*Cox regressions with backward stepwise method were used

Model 1 Adjusted by age, sex, BMI

Model 2 Adjusted by age, sex, BMI, smoking, hypertension, diabetes mellitus, BAV, atrial fibrillation, STS, and LVEF

BAV, bicuspid aortic valve; BMI, body mass index; CI, confidence interval; HR, hazard ratio; IR, incidence rate; STS, Society of Thoracic Surgeons; LVEF, left ventricular ejection fraction; TyG, triglyceride-glucose

Fig. 2 Kaplan-Meier cumulative survival analysis curves for all-cause mortality adjusted for age, sex and BMI for the higher TyG index and lower TyG index groups

The relationship between the TyG index and all-cause mortality was significantly modified by age (pinteraction = 0.027), sex (pinteraction = 0.007), hypertension (pinteraction = 0.030), and STS score (pinteraction = 0.002). The TyG index had higher hazard ratio for all-cause mortality in patients with severe AS underwent TAVR in the subgroup of those aged ≥ 75 years (HR 1.42, 95% CI 1.00-2.01, p = 0.047) compared with aged < 75 yeas (HR 0.77, 95% CI 0.37–1.63, p = 0.495), in the subgroup of male (HR 1.71, 95% CI 1.16–2.52, p = 0.007) compared with female (HR 0.92, 95% CI 0.50–1.71, p = 0.801), in the subgroup of hypertension (HR 1.52, 95% CI 1.03–2.26, p = 0.036) compared with no hypertension (HR 1.00, 95% CI 0.56–1.78, p = 0.030), in the subgroup of intermediate- or high-risk (HR 1.32, 95% CI 0.94–1.86, p = 0.110) compared with low-risk (HR 0.82, 95% CI 0.28–2.42, p = 0.714). Interaction and subgroup analysis was shown in Fig. 3.

Fig. 3 Subgroup analysis of the association between baseline TyG index and all-cause mortality. HR, hazard ratios; CI, confidence interval; BMI, body mass index; BAV, bicuspid aortic valve; STS, Society of Thoracic Surgeons; LVEF, left ventricular ejection fraction

Discussion

To the best of our knowledge, this study is the first study to examine the association between the TyG index and prognostic outcomes in patients with severe AS who have underwent TAVR. The main finding indicates that an elevated TyG index was significantly associated with an increased risk of all-cause mortality in these patients. Furthermore, the prognostic implication of a higher TyG index appears to be more pronounced in older patients, males, individuals with hypertension, and those with a higher STS risk score.

IR is a fundamental pathogenic factor in metabolic syndrome, encompassing conditions such as impaired glucose metabolism, dyslipidemia, obesity, and hypertension, all of which escalate the risk of CVD and mortality [21, 22]. The TyG index, derived from fasting blood glucose and triglyceride levels, has emerged as a straightforward and effective indicator of IR [17]. There is mounting evidence suggesting the TyG index’s association with both all-cause and cardiovascular mortality across the general populace and among individuals with various cardiometabolic disorders [16, 23–27]. Nonetheless, the literature remains sparse regarding the TyG index’s link to calcification or mortality in patients with AS [19, 28]. While the impact of metabolic syndrome on heart valve interventions has been acknowledged, investigations directly exploring the relationship between IR, as quantified by the TyG index, and mortality in AS patients undergoing TAVR are limited [29]. This study is the first to demonstrate a significant association between elevated IR, as quantified by the TyG index, and an enhanced risk of all-cause mortality among patients with severe AS undergoing TAVR, even after adjustments for potential confounders. Our findings highlight that the relationship between the TyG index and all-cause mortality is modified by age, sex, hypertension, and the STS score. This observation aligns with prior research, which has similarly reported that the association between the TyG index and mortality is modified by age and sex [30, 31].

The underlying mechanism connecting the TyG index with CVD remains elusive. However, it is evident that the TyG index encompasses two pivotal CVD risk factors, the lipid and glucose metabolism, indicative of IR in the body. IR itself is a recognized risk factor for CVD, implicated in the disease’s onset across both the general and diabetic populations, and is a predictor of cardiovascular outcomes [15]. A prior study involving 1574 patients, who presented with acute coronary syndrome and underwent successful percutaneous coronary intervention using drug-eluting stents, identified a positive, independent association between elevated TyG levels and the incidence of in-stent restenosis [32]. This relationship might be attributed to several mechanisms, including the excessive proliferation of vascular smooth muscle cells mediated by various signaling pathways, endothelial dysfunction through inflammation, oxidative stress, and metabolic changes [33–37]. Furthermore, as a surrogate marker for IR, the TyG index has been closely linked to both the prevalence and progression of coronary artery calcification, suggesting another potential mechanism [38, 39]. The initial phase of calcified AS mirrors atherosclerotic processes, where valve endothelial dysfunction arises from mechanical stress, inflammation, and lipid accumulation. Subsequent oxidative stress prompts the differentiation of valvular interstitial cells into myofibroblasts and osteoblast-like cells, fostering calcification and osteogenic alterations in the valve, thus exacerbating valve narrowing. The progression of calcified AS may, in certain contexts, be associated with IR or the TyG index [19, 28]. Nevertheless, additional research is required to fully decipher the mechanisms underlying the TyG index’s association with calcification and mortality.

A principal strength of our investigation is its novelty; to the best of our knowledge, this is the first study to assess the relationship between the TyG index and future mortality among patients with severe AS undergoing TAVR. An additional merit is our ability to track and analyze long-term outcomes spanning up to 8 years post-TAVR, offering valuable insights into patient prognoses over an extended period. Furthermore, the comprehensive dataset allows for detailed subgroup analyses and identification of potential effect modification. Critically, our findings carry significant clinical implications by suggesting the TyG index as a potential marker for risk stratification and management in AS patients post-TAVR. This underscores the necessity for future research to explore whether interventions targeting IR could yield benefits in this patient population. For instance, the use of Glucagon-like peptide-1 (GLP-1) analogs, known to mitigate major adverse cardiac events partly through their effects on vascular redox status and IR, points towards the therapeutic potential of addressing IR to enhance clinical outcomes [40].

Nonetheless, the present study has several potential limitations. Firstly, as a single-center, observational study, it cannot establish causality between the TyG index and all-cause mortality in patients with AS after TAVR. Although efforts were made to mitigate confounding through multivariate adjustments, the potential for residual confounding remains, which might affect the prognostic implications. Secondly, due to the absence of insulin level measurements and hyperinsulinemic-euglycemic clamp tests, this study could not evaluate the comparative prognostic relevance of the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and the TyG index in the post-TAVR mortality context. Thirdly, given that laboratory parameters were assessed only at the point of admission, the impact of changes in the TyG index over time on mortality outcomes is still uncertain, highlighting the need for future longitudinal studies to explore this aspect further. Fourthly, we were unable to record patients’ baseline medication data, which limits our ability to assess how current medications might affect triglyceride and glucose levels. Future research would benefit from including such data to provide a more comprehensive understanding of the factors influencing triglyceride and glucose levels.

Conclusions

In conclusion, our study is pioneering in demonstrating that an elevated TyG index is correlated with an increased risk of all-cause mortality in patients with severe AS who have undergone TAVR. These findings propose that the TyG index may serve as a viable prognostic marker for all-cause mortality in this patient population. Consequently, therapeutic interventions targeting insulin resistance could potentially enhance clinical outcomes for patients post-TAVR.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Author contributions

J.F., X.L., and J.W. contributed to the conception and design of the work; J.F., A.A., and A.Y. contributed to the acquisition, analysis, and interpretation of data; J.F. and A.A. drafted the manuscript; J.F., A.A., A.Y., X.L., and J.W. critically revised the manuscript. All authors gave final approval and agreed to be accountable for all aspects of work ensuring integrity and accuracy.

Funding

Not applicable.

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

Declarations

Ethical approval and consent to participate

All methods were carried out in accordance with the Declaration of Helsinki. The Ethics Review Committee of the Second Affiliated Hospital of Zhejiang University approved the study and written informed consents were obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Xianbao Liu and Jian’an Wang are joint corresponding authors.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Jiaqi Fan and Ailifeire Aihemaiti are co-first authors.
==== Refs
References

1. Smith CR Leon MB Mack MJ Miller DC Moses JW Svensson LG Transcatheter versus Surgical aortic-valve replacement in high-risk patients N Engl J Med 2011 364 2187 98 10.1056/NEJMoa1103510 21639811
Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus Surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187–98.21639811
2. Leon MB Smith CR Mack MJ Makkar RR Svensson LG Kodali SK Transcatheter or Surgical aortic-valve replacement in Intermediate-Risk patients N Engl J Med 2016 374 1609 20 10.1056/NEJMoa1514616 27040324
Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or Surgical aortic-valve replacement in Intermediate-Risk patients. N Engl J Med. 2016;374:1609–20.27040324
3. Mack MJ Leon MB Thourani VH Makkar R Kodali SK Russo M Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients N Engl J Med 2019 380 1695 705 10.1056/NEJMoa1814052 30883058
Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695–705.30883058
4. Reardon MJ Mieghem NM Van, Popma JJ Kleiman NS Søndergaard L Mumtaz M Surgical or Transcatheter aortic-valve replacement in Intermediate-Risk patients N Engl J Med 2017 376 1321 31 10.1056/NEJMoa1700456 28304219
Reardon MJ, Mieghem NM, Van, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M, et al. Surgical or Transcatheter aortic-valve replacement in Intermediate-Risk patients. N Engl J Med. 2017;376:1321–31.28304219
5. Adams DH Popma JJ Reardon MJ Yakubov SJ Coselli JS Deeb GM Transcatheter aortic-valve replacement with a self-expanding prosthesis N Engl J Med 2014 370 1790 8 10.1056/NEJMoa1400590 24678937
Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790–8.24678937
6. Popma JJ Deeb GM Yakubov SJ Mumtaz M Hemal Gada MD O’Hair D Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients N Engl J Med 2019 380 1706 15 10.1056/NEJMoa1816885 30883053
Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Hemal Gada MD, O’Hair D, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706–15.30883053
7. Mack MJ Leon MB Smith CR Miller DC Moses JW Tuzcu EM 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial Lancet 2015 385 2477 84 10.1016/S0140-6736(15)60308-7 25788234
Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2477–84.25788234
8. Jørgensen TH Thyregod HGH Ihlemann N Nissen H Petursson P Kjeldsen BJ Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement Eur Heart J 2021 42 2912 9 10.1093/eurheartj/ehab375 34179981
Jørgensen TH, Thyregod HGH, Ihlemann N, Nissen H, Petursson P, Kjeldsen BJ, et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart J. 2021;42:2912–9.34179981
9. van Bergeijk KH Wykrzykowska JJ van Mieghem NM Windecker S Sondergaard L Gada H Predicting 5-Year clinical outcomes after Transcatheter or Surgical aortic valve replacement (a risk score from the SURTAVI Trial) Am J Cardiol 2023 200 78 86 10.1016/j.amjcard.2023.05.036 37307783
van Bergeijk KH, Wykrzykowska JJ, van Mieghem NM, Windecker S, Sondergaard L, Gada H, et al. Predicting 5-Year clinical outcomes after Transcatheter or Surgical aortic valve replacement (a risk score from the SURTAVI Trial). Am J Cardiol. 2023;200:78–86.37307783
10. Lee CH Inohara T Hayashida K Park D-W Transcatheter aortic valve replacement in Asia JACC: Asia 2021 1 279 93 36341218
Lee CH, Inohara T, Hayashida K, Park D-W. Transcatheter aortic valve replacement in Asia. JACC: Asia. 2021;1:279–93.36341218
11. Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Front Endocrinol. 2023;14 March.
12. Laakso M Kuusisto J Insulin resistance and hyperglycaemia in cardiovascular disease development Nat Rev Endocrinol 2014 10 293 302 10.1038/nrendo.2014.29 24663222
Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10:293–302.24663222
13. Liu L, Peng J, Wang N, Wu Z, Zhang Y, Cui H et al. Comparison of seven surrogate insulin resistance indexes for prediction of incident coronary heart disease risk: a 10-year prospective cohort study. Front Endocrinol (Lausanne). 2024;15.
14. Tao LC, Xu J, ni, Wang T ting, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21:1–17.
15. Hill MA Yang Y Zhang L Sun Z Jia G Parrish AR Insulin resistance, cardiovascular stiffening and cardiovascular disease Metabolism 2021 119 154766 10.1016/j.metabol.2021.154766 33766485
Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119:154766.33766485
16. Lopez-Jaramillo P Gomez-Arbelaez D Martinez-Bello D Abat MEM Alhabib KF Avezum Á Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study Lancet Healthy Longev 2023 4 e23 33 10.1016/S2666-7568(22)00247-1 36521498
Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, Abat MEM, Alhabib KF, Avezum Á, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. Lancet Healthy Longev. 2023;4:e23–33.36521498
17. Guerrero-Romero F Simental-Mendía LE González-Ortiz M Martínez-Abundis E Ramos-Zavala MG Hernández-González SO The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the Euglycemic-Hyperinsulinemic Clamp J Clin Endocrinol Metab 2010 95 3347 51 10.1210/jc.2010-0288 20484475
Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, Martínez-Abundis E, Ramos-Zavala MG, Hernández-González SO, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the Euglycemic-Hyperinsulinemic Clamp. J Clin Endocrinol Metab. 2010;95:3347–51.20484475
18. Minh H Van, Tien HA Sinh CT Thang DC Chen C Tay JC Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension J Clin Hypertens 2021 23 529 37 10.1111/jch.14155
Minh H, Van, Tien HA, Sinh CT, Thang DC, Chen C, Tay JC, et al. Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension. J Clin Hypertens. 2021;23:529–37.
19. Huang R Xu X Xu C Zhang S Xiong Z Liu M Association between the insulin resistance and all-cause mortality in patients with moderate and severe aortic stenosis: a retrospective cohort study Cardiovasc Diabetol 2023 22 1 10 10.1186/s12933-023-01975-5 36609317
Huang R, Xu X, Xu C, Zhang S, Xiong Z, Liu M, et al. Association between the insulin resistance and all-cause mortality in patients with moderate and severe aortic stenosis: a retrospective cohort study. Cardiovasc Diabetol. 2023;22:1–10.36609317
20. Fan J Fang X Liu C Zhu G Hou CR Jiang J Brain Injury after Transcatheter replacement of Bicuspid Versus Tricuspid aortic valves J Am Coll Cardiol 2020 76 2579 90 10.1016/j.jacc.2020.09.605 33243378
Fan J, Fang X, Liu C, Zhu G, Hou CR, Jiang J, et al. Brain Injury after Transcatheter replacement of Bicuspid Versus Tricuspid aortic valves. J Am Coll Cardiol. 2020;76:2579–90.33243378
21. Cai X, Zhang Y, Li M, Wu JH, Mai L, Li J et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;:m2297.
22. Sundström J Risérus U Byberg L Zethelius B Lithell H Lind L Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study BMJ 2006 332 878 82 10.1136/bmj.38766.624097.1F 16510492
Sundström J, Risérus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ. 2006;332:878–82.16510492
23. Xu X Huang R Lin Y Guo Y Xiong Z Zhong X High triglyceride-glucose index in young adulthood is associated with incident cardiovascular disease and mortality in later life: insight from the CARDIA study Cardiovasc Diabetol 2022 21 155 10.1186/s12933-022-01593-7 35962377
Xu X, Huang R, Lin Y, Guo Y, Xiong Z, Zhong X, et al. High triglyceride-glucose index in young adulthood is associated with incident cardiovascular disease and mortality in later life: insight from the CARDIA study. Cardiovasc Diabetol. 2022;21:155.35962377
24. Yu Y Gu M Huang H Cheng S Deng Y Cai C Combined association of triglyceride-glucose index and systolic blood pressure with all-cause and cardiovascular mortality among the general population J Transl Med 2022 20 478 10.1186/s12967-022-03678-z 36266665
Yu Y, Gu M, Huang H, Cheng S, Deng Y, Cai C, et al. Combined association of triglyceride-glucose index and systolic blood pressure with all-cause and cardiovascular mortality among the general population. J Transl Med. 2022;20:478.36266665
25. Zhang R Shi S Chen W Wang Y Lin X Zhao Y Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database Cardiovasc Diabetol 2023 22 10 10.1186/s12933-023-01737-3 36639637
Zhang R, Shi S, Chen W, Wang Y, Lin X, Zhao Y, et al. Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database. Cardiovasc Diabetol. 2023;22:10.36639637
26. Luo E Wang D Yan G Qiao Y Liu B Hou J High triglyceride–glucose index is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention Cardiovasc Diabetol 2019 18 150 10.1186/s12933-019-0957-3 31722708
Luo E, Wang D, Yan G, Qiao Y, Liu B, Hou J, et al. High triglyceride–glucose index is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention. Cardiovasc Diabetol. 2019;18:150.31722708
27. Ma X Dong L Shao Q Cheng Y Lv S Sun Y Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome Cardiovasc Diabetol 2020 19 31 10.1186/s12933-020-01006-7 32156279
Ma X, Dong L, Shao Q, Cheng Y, Lv S, Sun Y, et al. Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome. Cardiovasc Diabetol. 2020;19:31.32156279
28. Hu Z Xiong T Chen C Chen T Li M Liang J Association between the triglyceride-glucose index and calcified aortic stenosis in elderly patients: a cross-sectional study Sci Rep 2023 13 1 8 36593249
Hu Z, Xiong T, Chen C, Chen T, Li M, Liang J, et al. Association between the triglyceride-glucose index and calcified aortic stenosis in elderly patients: a cross-sectional study. Sci Rep. 2023;13:1–8.36593249
29. Moscarelli M Paparella D Angelini GD Giannini F Contegiacomo G Marchese A The influence of metabolic syndrome in heart valve intervention. A multi-centric study J Card Surg 2022 37 5063 72 10.1111/jocs.17204 36413686
Moscarelli M, Paparella D, Angelini GD, Giannini F, Contegiacomo G, Marchese A, et al. The influence of metabolic syndrome in heart valve intervention. A multi-centric study. J Card Surg. 2022;37:5063–72.36413686
30. Yao Y Wang B Geng T Chen J Chen W Li L The association between TyG and all-cause/non-cardiovascular mortality in general patients with type 2 diabetes mellitus is modified by age: results from the cohort study of NHANES 1999–2018 Cardiovasc Diabetol 2024 23 1 12 10.1186/s12933-024-02120-6 38172989
Yao Y, Wang B, Geng T, Chen J, Chen W, Li L. The association between TyG and all-cause/non-cardiovascular mortality in general patients with type 2 diabetes mellitus is modified by age: results from the cohort study of NHANES 1999–2018. Cardiovasc Diabetol. 2024;23:1–12.38172989
31. Dai L, Yu Y, Wang K, Hu C, Wu D, Shan S. Association between TyG index and long-term mortality of critically ill patients: a retrospective study based on the MIMIC database. BMJ Open. 2023;13.
32. Zhu Y Liu K Chen M Liu Y Gao A Hu C Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents Cardiovasc Diabetol 2021 20 137 10.1186/s12933-021-01332-4 34238294
Zhu Y, Liu K, Chen M, Liu Y, Gao A, Hu C, et al. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents. Cardiovasc Diabetol. 2021;20:137.34238294
33. Dangas GD Claessen BE Caixeta A Sanidas EA Mintz GS Mehran R In-Stent restenosis in the drug-eluting stent era J Am Coll Cardiol 2010 56 1897 907 10.1016/j.jacc.2010.07.028 21109112
Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-Stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897–907.21109112
34. Qi W Li Q Liew CW Rask-Madsen C Lockhart SM Rasmussen LM SHP-1 activation inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in a rodent model of insulin resistance and diabetes Diabetologia 2017 60 585 96 10.1007/s00125-016-4159-1 27933336
Qi W, Li Q, Liew CW, Rask-Madsen C, Lockhart SM, Rasmussen LM, et al. SHP-1 activation inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in a rodent model of insulin resistance and diabetes. Diabetologia. 2017;60:585–96.27933336
35. Lafont A Durand E Samuel JL Besse B Addad F Lévy BI Endothelial dysfunction and collagen Accumulation Circulation 1999 100 1109 15 10.1161/01.CIR.100.10.1109 10477537
Lafont A, Durand E, Samuel JL, Besse B, Addad F, Lévy BI, et al. Endothelial dysfunction and collagen Accumulation. Circulation. 1999;100:1109–15.10477537
36. Kitta Y Nakamura T Kodama Y Takano H Umetani K Fujioka D Endothelial vasomotor dysfunction in the Brachial artery is Associated with Late In-Stent coronary restenosis J Am Coll Cardiol 2005 46 648 55 10.1016/j.jacc.2005.04.055 16098430
Kitta Y, Nakamura T, Kodama Y, Takano H, Umetani K, Fujioka D, et al. Endothelial vasomotor dysfunction in the Brachial artery is Associated with Late In-Stent coronary restenosis. J Am Coll Cardiol. 2005;46:648–55.16098430
37. Bornfeldt KE Tabas I Insulin resistance, hyperglycemia, and atherosclerosis Cell Metab 2011 14 575 85 10.1016/j.cmet.2011.07.015 22055501
Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14:575–85.22055501
38. Park K Ahn CW Lee SB Kang S Nam JS Lee BK Elevated TyG index predicts progression of coronary artery calcification Diabetes Care 2019 42 1569 73 10.2337/dc18-1920 31182490
Park K, Ahn CW, Lee SB, Kang S, Nam JS, Lee BK, et al. Elevated TyG index predicts progression of coronary artery calcification. Diabetes Care. 2019;42:1569–73.31182490
39. Kim MK Ahn CW Kang S Nam JS Kim KR Park JS Relationship between the triglyceride glucose index and coronary artery calcification in Korean adults Cardiovasc Diabetol 2017 16 108 10.1186/s12933-017-0589-4 28830471
Kim MK, Ahn CW, Kang S, Nam JS, Kim KR, Park JS. Relationship between the triglyceride glucose index and coronary artery calcification in Korean adults. Cardiovasc Diabetol. 2017;16:108.28830471
40. Andrikou E Tsioufis C Andrikou I Leontsinis I Tousoulis D Papanas N GLP-1 receptor agonists and cardiovascular outcome trials: an update Hellenic J Cardiol 2019 60 347 51 10.1016/j.hjc.2018.11.008 30528435
Andrikou E, Tsioufis C, Andrikou I, Leontsinis I, Tousoulis D, Papanas N. GLP-1 receptor agonists and cardiovascular outcome trials: an update. Hellenic J Cardiol. 2019;60:347–51.30528435
